Bile salt export pump
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Bile salt export pump as ChEMBL target CHEMBL6020, mapped to UniProt O95342. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Bile salt export pump matters
Bile salt export pump is reviewed as Bile salt export pump (UniProt O95342); the current evidence base includes 194 approved drugs, 1475 compounds, and 80 assays, with lead potency reaching pChEMBL 7.0.
Bile salt export pump Sequence length is 1321 aa.
Review this target as Bile salt export pump, mapped to UniProt O95342. Sequence length is 1321 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 194 approved drugs, 1475 compounds, and 80 assays for this target. The dominant activity type is IC50. CHEMBL1651956 is the current potency anchor at pChEMBL 7.0.
Use CHEMBL1651956 as the tractability anchor when discussing potency (pChEMBL 7.0).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Bile salt export pump matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt O95342, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL1651956
|
7.0 | IC50 | Clinical |
|
|
No preferred name
CHEMBL3704745
|
6.8 | IC50 | — |
|
|
No preferred name
CHEMBL595
|
6.6 | IC50 | Approved |
|
|
No preferred name
CHEMBL4162778
|
6.5 | IC50 | — |
|
|
No preferred name
CHEMBL160
|
6.4 | IC50 | Approved |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
PIOGLITAZONE
CHEMBL595
|
1999 |
|
|
CYCLOSPORINE
CHEMBL160
|
1983 |